JP2024540148A - Ｇｐｒｃ５ｄに結合する抗体及びその使用 - Google Patents

Ｇｐｒｃ５ｄに結合する抗体及びその使用 Download PDF

Info

Publication number
JP2024540148A
JP2024540148A JP2024525546A JP2024525546A JP2024540148A JP 2024540148 A JP2024540148 A JP 2024540148A JP 2024525546 A JP2024525546 A JP 2024525546A JP 2024525546 A JP2024525546 A JP 2024525546A JP 2024540148 A JP2024540148 A JP 2024540148A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540148A5 (https=
Inventor
ルー、チェンチェン
ワン、ユージエ
ペン、シュアンリー
チャン、チェンピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2024540148A publication Critical patent/JP2024540148A/ja
Publication of JP2024540148A5 publication Critical patent/JP2024540148A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024525546A 2021-11-05 2022-11-04 Ｇｐｒｃ５ｄに結合する抗体及びその使用 Pending JP2024540148A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111305149 2021-11-05
CN202111305149.7 2021-11-05
PCT/CN2022/129803 WO2023078382A1 (zh) 2021-11-05 2022-11-04 结合gprc5d的抗体及其用途

Publications (2)

Publication Number Publication Date
JP2024540148A true JP2024540148A (ja) 2024-10-31
JP2024540148A5 JP2024540148A5 (https=) 2025-11-12

Family

ID=86240662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525546A Pending JP2024540148A (ja) 2021-11-05 2022-11-04 Ｇｐｒｃ５ｄに結合する抗体及びその使用

Country Status (6)

Country Link
EP (1) EP4428153A4 (https=)
JP (1) JP2024540148A (https=)
KR (1) KR20240099351A (https=)
CN (1) CN118159565A (https=)
TW (1) TW202334222A (https=)
WO (1) WO2023078382A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925229B (zh) * 2023-09-19 2023-12-15 南京驯鹿生物技术股份有限公司 一种靶向gprc5d的抗体及其应用
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
US12545726B1 (en) 2025-07-22 2026-02-10 Integral Molecular, Inc. Compositions and methods related to GPRC5D binding agents and variants thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017011932A8 (pt) * 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
SG11201907321TA (en) * 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
BR112021013824A2 (pt) * 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
CA3248329A1 (en) * 2019-07-31 2025-11-29 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d

Also Published As

Publication number Publication date
WO2023078382A1 (zh) 2023-05-11
EP4428153A4 (en) 2026-02-11
KR20240099351A (ko) 2024-06-28
EP4428153A1 (en) 2024-09-11
TW202334222A (zh) 2023-09-01
CN118159565A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
JP2024540148A (ja) Ｇｐｒｃ５ｄに結合する抗体及びその使用
JP7604379B2 (ja) 抗ｐｄ－１抗体、その抗原結合フラグメントおよびそれらの医薬用途
JP7397897B2 (ja) ヒトｐｄ－ｌ１に結合する抗体
CA3206838A1 (en) Pd-1 binding molecule and application thereof
CN113840836B (zh) 抗结缔组织生长因子抗体及其应用
TW202128765A (zh) 一種雙特異性抗體
CN109721656A (zh) 靶向rankl的治疗性抗体
AU2024225804A1 (en) Antibodies, antigen-binding fragments and methods of use
CN116368153A (zh) Zip12抗体
IL324067A (en) Bispecific antibody targeting g protein-coupled receptor
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20220135686A1 (en) Antibody that binds to human pd-l1
CN117964772A (zh) NKp80-CD155双特异性抗体及其应用
CN118556082A (zh) p95HER2抗体及其应用
WO2023178645A1 (zh) 靶向cd3的抗体及其应用
WO2024012513A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
AU2024331841A1 (en) Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof
JP2026513553A (ja) 抗ｂｄｃａ２抗体
JP2026506623A (ja) 抗ｃｄｈ６抗体及びその使用
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用
CN118894943A (zh) 靶向密蛋白的双特异性抗体
CN118894944A (zh) 抗密蛋白双特异性抗体
CN117886935A (zh) 抗csf-1r抗体及其应用
HK40064840B (en) Anti-connective tissue growth factor antibody and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251031